EGFR-based bioradiotherapy in SCCHN

Affiliations

¹ Department of Medicine and Comprehensive Cancer Research Center, University of Chicago Medicine and Biological Sciences, 5841 S Maryland Avenue, MC2115, Chicago, IL 60637, USA.
² Department of Medicine and Comprehensive Cancer Research Center, University of Chicago Medicine and Biological Sciences, 5841 S Maryland Avenue, MC2115, Chicago, IL 60637, USA. Electronic address: evokes@medicine.bsd.uchicago.edu.

Comment

Vassiliki Saloura et al. Lancet Oncol. 2015 Feb.

. 2015 Feb;16(2):129-30.

doi: 10.1016/S1470-2045(15)70006-9. Epub 2015 Jan 15.

¹ Department of Medicine and Comprehensive Cancer Research Center, University of Chicago Medicine and Biological Sciences, 5841 S Maryland Avenue, MC2115, Chicago, IL 60637, USA.
² Department of Medicine and Comprehensive Cancer Research Center, University of Chicago Medicine and Biological Sciences, 5841 S Maryland Avenue, MC2115, Chicago, IL 60637, USA. Electronic address: evokes@medicine.bsd.uchicago.edu.

No abstract available

Comment on

Panitumumab plus radiotherapy versus chemoradiotherapy in patients with unresected, locally advanced squamous-cell carcinoma of the head and neck (CONCERT-2): a randomised, controlled, open-label phase 2 trial.
Giralt J, Trigo J, Nuyts S, Ozsahin M, Skladowski K, Hatoum G, Daisne JF, Yunes Ancona AC, Cmelak A, Mesía R, Zhang A, Oliner KS, VanderWalde A. Giralt J, et al. Lancet Oncol. 2015 Feb;16(2):221-32. doi: 10.1016/S1470-2045(14)71200-8. Epub 2015 Jan 15. Lancet Oncol. 2015. PMID: 25596659 Clinical Trial.
Chemoradiotherapy with or without panitumumab in patients with unresected, locally advanced squamous-cell carcinoma of the head and neck (CONCERT-1): a randomised, controlled, open-label phase 2 trial.
Mesía R, Henke M, Fortin A, Minn H, Yunes Ancona AC, Cmelak A, Markowitz AB, Hotte SJ, Singh S, Chan AT, Merlano MC, Skladowski K, Zhang A, Oliner KS, VanderWalde A, Giralt J. Mesía R, et al. Lancet Oncol. 2015 Feb;16(2):208-20. doi: 10.1016/S1470-2045(14)71198-2. Epub 2015 Jan 15. Lancet Oncol. 2015. PMID: 25596660 Clinical Trial.